Mobile

A randomised, parallel arm, open-label trial comparing degarelix with goserelin plus anti-androgen flare protection (bicalutamide), in terms of prostate size reduction in prostate cancer patients of i...

Mise à jour : Il y a 4 ans
Référence : EUCTR2008-005232-33

A randomised, parallel arm, open-label trial comparing degarelix with goserelin plus anti-androgen flare protection (bicalutamide), in terms of prostate size reduction in prostate cancer patients of intermediate-to-high risk, who require neoadjuvant hormone therapy prior to radiotherapy (curative intent)

  • | Pays :
    • -
  • | Organes :
    • -
  • | Spécialités :
    • -

Extrait

To demonstrate that the mean percentage reduction in prostate volume with degarelix is non-inferior to goserelin plus bicalutamide, based on a trans-rectal ultrasound scan (TRUS) at 12 weeks (Visit 5=End of Trial [EoT] Visit) compared to baseline (Visit 2 - Randomisation)

Critère d'inclusion

  • Prostate cancer

Liens